Effects of Ticlopidine to In-vitro Platelet Aggregation Response Induced by Agonists in Coronary Stenting Patients [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2002; 30(1): 16-21

Effects of Ticlopidine to In-vitro Platelet Aggregation Response Induced by Agonists in Coronary Stenting Patients

Abdi SAĞCAN1, Mustafa AKIN2, Serdar Bedii OMAY3, Azem AKILLI4, Cüneyt TÜRKOĞLU2
1
2
3
4

Coronary artery stenting (CAS) is used in patients with localized coronary stenosis, and for suboptimal results after PTCA as an alternative treatment to bypass surgery. Ischemic complications after PTCA and CAS may be caused by activation of the hemostatic system by the maneuver. Conventional therapies with antiplatelet and anticoagulant agents cannot completely prevent platelet aggregation and thrombosis. Ticlopidine has been shown to inhibit ADP-induced ex-vivo platelet aggregation in healthy subjects. In this study, effects of ticlopidine on in vitro platelet aggregation seen after CAS were investigated. Study population consisted of 38 patients (mean age: 57±9, number of vessels: 39, number of stents: 42, pre-procedural luminal stenosis: 93±7%, post-procedural luminal stenosis: 4±2%) who had successful coronary stenting and homogenous medical therapy (aspirin and oral nitrate). Ticlopidine 500 mg was given to all patients just before stent application and continued for one month at the same dose. Platelet rich plasma before, immediately after, and 8 days after the procedure were obtained, incubated with ADP, collagen and epinephrine separately. Turbidimetric method of Born was used for amplitude and duration of aggregation value measurements. All data were compared by repeated test ANOVA Only collagen-induced aggregation duration was increased significantly (p<0.001) immediately after coronary stenting measurements, and approached to normal (p>0.05) at the 8th day after stenting. Aggregation amplitude immediately after stenting was increased and decreased insignificantly (p>0.05) by collagen-epinephrine and ADP, respectively. Aggregation amplitude was found significantly decreased (p<0.05-<0.001) at the 8th day after intervention. In conlusion, standard antiaggregant therapy inhibits in-vitro platelet aggregation sufficiently in elective coronary stenting patients; moreover, ticlopidine combination to this procedure may lead to additive effect.


How to cite this article
Abdi SAĞCAN, Mustafa AKIN, Serdar Bedii OMAY, Azem AKILLI, Cüneyt TÜRKOĞLU. Effects of Ticlopidine to In-vitro Platelet Aggregation Response Induced by Agonists in Coronary Stenting Patients. Turk Kardiyol Dern Ars. 2002; 30(1): 16-21
© Copyright 2019 Archives of the Turkish Society of Cardiology
LookUs & Online Makale